Pegloticase: A Novel Agent for Treatment-Refractory Gout

New advances in the treatment of gout: review of pegloticase

(2016) Mark Reinders   Therapeutics and Clinical Risk Management

The Challenges of Gout Management in the Elderly

(2011) Lisa K. Stamp et al.   DRUGS & AGING

Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment

(2011)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Chronic gout: epidemiology, disease progression, treatment and disease burden

(2010) Richard A. Brook et al.   CURRENT MEDICAL RESEARCH AND OPINION

Gout therapeutics: new drugs for an old disease

(2010) Christopher M Burns et al.   LANCET

Update on gout: new therapeutic strategies and options

(2010) Robert Terkeltaub   Nature Reviews Rheumatology

Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy

(2010) N.L. Edwards et al.   JOURNAL OF MEDICAL ECONOMICS

Quality of Life and Disability in Patients with Treatment-Failure Gout

(2009) M. A. BECKER et al.   JOURNAL OF RHEUMATOLOGY

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study

(2008) John S. Sundy et al.   ARTHRITIS AND RHEUMATISM

Population Pharmacokinetic and Pharmacodynamic Analysis of Pegloticase in Subjects With Hyperuricemia and Treatment-Failure Gout

(2008) Corinne Seng Yue et al.   JOURNAL OF CLINICAL PHARMACOLOGY

PEG-uricase in the management of treatment-resistant gout and hyperuricemia

(2007) Merry R. Sherman et al.   ADVANCED DRUG DELIVERY REVIEWS